It's Time to Revisit R&D Partnerships to Fund Biotech Companies
Biotechs who are agonizingly close to delivering breatkhrough products that will change medical practice cann't persuade investors to see the value that lies within this powerful industry. The solution is to reintroduce the tax breaks for investors via R&D Limited Partnerships.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.